The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.

An AI-enabled wearable sensor with vibratory feedback significantly reduces nocturnal scratching in atopic dermatitis, ...

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

The following is a summary of “Impact of COVID-19 disease and vaccination on dermatological immune-mediated inflammatory ...

Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.

Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...

A new medicine, Nenolizumab, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat two ...

Apple cider vinegar is fermented juice made from apples. It may be useful in blood sugar management, weight loss, and ...

Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...

As everyone knows, scratching at chronically itchy skin only makes the problem worse. A new device is claimed to help stop ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

The webcast for this conference may be accessed at the“Events” section of the Company's website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.